Actuate announces preclinical combo synergy for elraglusib
Actuate said preclinical data show synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.